Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
D 94.16 0.09% 0.08
BPMC closed up 0.09 percent on Friday, April 9, 2021, on 51 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical BPMC trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Hammer Candlestick Bullish 0.00%
Doji - Bullish? Reversal 0.00%
Crossed Above 200 DMA Bullish 0.09%
Inside Day Range Contraction 0.09%
Fell Below 200 DMA Bearish 1.25%
Gapped Down Weakness 1.25%
Fell Below 20 DMA Bearish -2.95%
Fell Below 50 DMA Bearish -2.95%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.95%
Older End-of-Day Signals for BPMC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 16 hours ago
200 DMA Support about 21 hours ago
Down 2 % about 21 hours ago
Down 1% about 22 hours ago
Fell Below 200 DMA about 22 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Blueprint Medicines Corporation Description

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Gastrointestinal Cell Biology Genetic Disease Tyrosine Kinase Genetic Diseases Tyrosine Kinase Receptors Protein Kinase Inhibitor Cell Signaling Fibroblast Growth Factor Receptor Rare Genetic Disease Rare Genetic Diseases Gastrointestinal Stromal Tumor Mastocytosis Systemic Mastocytosis Receptor Tyrosine Kinase Mast Cell Myeloproliferative Neoplasm

Is BPMC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 125.61
52 Week Low 56.0
Average Volume 410,854
200-Day Moving Average 93.62
50-Day Moving Average 98.38
20-Day Moving Average 98.76
10-Day Moving Average 95.50
Average True Range 4.36
ADX 18.68
+DI 17.48
-DI 29.52
Chandelier Exit (Long, 3 ATRs ) 95.04
Chandelier Exit (Short, 3 ATRs ) 102.35
Upper Bollinger Band 108.20
Lower Bollinger Band 89.31
Percent B (%b) 0.26
BandWidth 19.12
MACD Line -1.34
MACD Signal Line -0.92
MACD Histogram -0.4196
Fundamentals Value
Market Cap 5.25 Billion
Num Shares 55.7 Million
EPS 6.18
Price-to-Earnings (P/E) Ratio 15.24
Price-to-Sales 7.13
Price-to-Book 4.53
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 98.11
Resistance 3 (R3) 97.78 96.15 97.45
Resistance 2 (R2) 96.15 95.14 96.31 97.23
Resistance 1 (R1) 95.15 94.52 94.34 95.48 97.01
Pivot Point 93.52 93.52 93.11 93.68 93.52
Support 1 (S1) 92.52 92.51 91.71 92.85 91.31
Support 2 (S2) 90.89 91.89 91.05 91.09
Support 3 (S3) 89.89 90.89 90.87
Support 4 (S4) 90.22